Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

As of close of business last night, Aclaris Therapeutics Inc’s stock clocked out at $2.13, up 2.40% from its previous closing price of $2.08. In other words, the price has increased by $2.40 from its previous closing price. On the day, 0.74 million shares were traded. ACRS stock price reached its highest trading level at $2.155 during the session, while it also had its lowest trading level at $2.08.

Ratios:

To gain a deeper understanding of ACRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.88 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 230747168 and an Enterprise Value of 133307624. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.74 while its Price-to-Book (P/B) ratio in mrq is 1.75. Its current Enterprise Value per Revenue stands at 7.94 whereas that against EBITDA is -2.288.

Stock Price History:

The Beta on a monthly basis for ACRS is 0.29, which has changed by 0.8050847 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 26.21%, while the 200-Day Moving Average is calculated to be 7.81%.

Shares Statistics:

It appears that ACRS traded 1.11M shares on average per day over the past three months and 643110 shares per day over the past ten days. A total of 108.33M shares are outstanding, with a floating share count of 92.29M. Insiders hold about 14.81% of the company’s shares, while institutions hold 72.89% stake in the company. Shares short for ACRS as of 1755216000 were 5982293 with a Short Ratio of 5.39, compared to 1752537600 on 7775760. Therefore, it implies a Short% of Shares Outstanding of 5982293 and a Short% of Float of 6.5799996.

Earnings Estimates

The current rating of Aclaris Therapeutics Inc (ACRS) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.16.

Analysts are recommending an EPS of between -$0.51 and -$0.55 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.62, with 5.0 analysts recommending between -$0.41 and -$0.87.

Revenue Estimates

In the current quarter, 6 analysts expect revenue to total $1.59M. It ranges from a high estimate of $2.1M to a low estimate of $1M. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $4.35MFor the next quarter, 6 analysts are estimating revenue of $1.57M. There is a high estimate of $1.97M for the next quarter, whereas the lowest estimate is $1M.

A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.2M, while the lowest revenue estimate was $5.2M, resulting in an average revenue estimate of $6.34M. In the same quarter a year ago, actual revenue was $18.72MBased on 8 analysts’ estimates, the company’s revenue will be $5.05M in the next fiscal year. The high estimate is $10M and the low estimate is $900k.